Insight Molecular Diagnostics (NASDAQ:IMDX - Get Free Report) had its price objective reduced by analysts at Lake Street Capital to $9.00 in a report released on Friday, Benzinga reports. The firm presently has a "buy" rating on the stock. Lake Street Capital's price objective suggests a potential upside of 397.24% from the stock's current price.
A number of other brokerages also recently commented on IMDX. Stephens reiterated an "equal weight" rating and issued a $4.00 price objective on shares of Insight Molecular Diagnostics in a research report on Wednesday. Needham & Company LLC restated a "buy" rating and issued a $9.00 target price on shares of Insight Molecular Diagnostics in a research note on Tuesday, August 18th. Weiss Ratings restated a "sell (d-)" rating on shares of Insight Molecular Diagnostics in a research note on Monday, September 21st. BTIG Research reiterated a "neutral" rating and set a $1.00 price target on shares of Insight Molecular Diagnostics in a research note on Wednesday. Finally, Wall Street Zen lowered shares of Insight Molecular Diagnostics from a "hold" rating to a "sell" rating in a report on Saturday, October 3rd. Two research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Hold" and a consensus target price of $5.75.
Get Our Latest Stock Analysis on Insight Molecular Diagnostics
Insight Molecular Diagnostics Stock Up 9.0%
Insight Molecular Diagnostics stock traded up $0.15 during mid-day trading on Friday, reaching $1.81. The company had a trading volume of 919,721 shares, compared to its average volume of 240,938. The firm has a market cap of $59.30 million, a price-to-earnings ratio of -1.46 and a beta of 1.90. The company has a 50 day moving average of $3.10 and a 200-day moving average of $4.45. Insight Molecular Diagnostics has a 52 week low of $1.50 and a 52 week high of $7.51.
Insight Molecular Diagnostics (NASDAQ:IMDX - Get Free Report) last released its earnings results on Monday, November 16th. The company reported ($0.19) earnings per share for the quarter. The company had revenue of $0.56 million for the quarter.
Insider Activity at Insight Molecular Diagnostics
In other news, major shareholder Broadwood Partners, L.P. bought 3,428,571 shares of the stock in a transaction dated Tuesday, November 17th. The shares were acquired at an average price of $1.75 per share, with a total value of $5,999,999.25. Following the acquisition, the insider owned 16,113,455 shares in the company, valued at $28,198,546.25. This trade represents a 27.03% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 2.21% of the company's stock.
Insight Molecular Diagnostics Company Profile
(
Get Free Report)
Oncocyte Corporation, now known as Insight Molecular Diagnostics, Inc. NASDAQ: IMDX, is a molecular diagnostics company focused on monitoring organ transplants. Its tests analyze donor-derived cell-free DNA in a transplant recipient's blood to help assess graft health and identify signs of potential injury or rejection. The company's VitaGraft tests include assays for kidney and liver transplant monitoring. These laboratory-developed tests are processed through the company's clinical laboratory and are intended to provide clinicians with information that can complement other aspects of post-transplant care.
Recommended Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Insight Molecular Diagnostics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Insight Molecular Diagnostics wasn't on the list.
While Insight Molecular Diagnostics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Could the next Tesla, NVIDIA, and Google be hiding in plain sight? Discover seven growth stocks with the potential to become tomorrow's market giants, fueled by breakthroughs in AI, nuclear energy, cybersecurity, and more.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.